Literature DB >> 32420613

Atypical lymphocytes in peripheral blood of patients with COVID-19.

Samuel E Weinberg1, Amir Behdad1, Peng Ji1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32420613      PMCID: PMC7276903          DOI: 10.1111/bjh.16848

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   8.615


× No keyword cloud information.
The outbreak of coronavirus disease 2019 (COVID‐19) in December 2019 in Wuhan, China, rapidly became a pandemic across the world, including the USA. Since March 2020, we started to receive peripheral blood smear review consults for patients who were admitted with COVID‐19. We reviewed 15 peripheral blood smears from the 15 most recently admitted patients Table I. These patients ranged in age from 26 to 90 years and included eight males and seven females. The reasons for peripheral blood smear consult were primarily concerns for haemolysis (nine of the 15 cases), followed by anaemia, thrombocytopenia and pancytopenia.
Table I

Full blood count of the 15 patients with COVID‐19 accompanying the blood smear review in Fig 1.

ID no.Age, years

Location/

disposition

% atypical Lympho.WBC, K/μlRBC, M/μlHb, g/lHct, %MCV, flMCH, pgMCHC,%RDW, %PLT, K/μlMPV, flAbsolute neutrophil, K/μlAbsolute lymphocyte, K/μlAbsolute monocyte, K/μlAbsolute eosinophil, K/μlAbsolute basophil, K/μl
172ICU10162·036821·610633·531·514·628711·211·430·20·20·2
243Medicine Floor0·53·92·938327·59428·330·212·122810·61·81·50·500
337ED147·54·4511835·48026·533·315·67312·66·20·70·400·1
466ICU914·62·367124·510430·12916·940711·211·10·6200·1
568ICU210·62·417122·39229·531·813·7232118·810·70·10
654ICU13·513·52·587323·19028·331·616·422911·111·20·51·10·10·1
758Medicine Floor128·45·716649·18629·133·812·931510·76·41·50·500
875ICU69·63·7310829·8802936·21514410·981·10·30·10
942ICU423·72·567824·59630·531·815·815812·920·41·22·100
1065ICU918·82·967424·5832530·218·244311·715·61·51·700
1170Medicine Floor62·35·5612541·97522·529·816·776N/A1·60·50·20·10
1226Medicine Floor31·63·4610731·99230·933·512·820710·30·80·40·400
1390ICU417·14·211335·78526·931·716·765N/A15·70·50·300
1454Medicine Floor101·92·658424·49231·734·411·912210·71·30·20·200
1572ICU043·9411734·78829·733·712·2979·52·21·50·200

Hb, haemoglobin; Hct, haematocrit; ICU, intensive care unit; ID, identification; MCH(C), mean corpuscular Hb (concentration); MCV, mean corpuscular volume; MPV, mean platelet volume; RBC, red blood cell; PLT, platelets; RDW, red cell distribution width; WBC, white blood cell.

Full blood count of the 15 patients with COVID‐19 accompanying the blood smear review in Fig 1.
Fig 1

Atypical lymphocytes in patients with COVID‐19. (A–C) Wright‐Giemsa stained peripheral blood smear showing representative forms of atypical lymphocytes observed in 15 cases of smear review (×100). (D) Percentages of indicated lymphocytes out of total lymphocytes in the patients with COVID‐19. Differential count of the indicated lymphocytes was performed; 200 lymphocytes were counted in each patient. (E) Wright‐Giemsa stained bronchial alveolar lavage smear from a patient with COVID‐19 (×60). (F) Wright‐Giemsa stain of the peripheral blood smear from a patient with infectious mononucleosis caused by Epstein–Barr virus infection (×100).

Location/ disposition Hb, haemoglobin; Hct, haematocrit; ICU, intensive care unit; ID, identification; MCH(C), mean corpuscular Hb (concentration); MCV, mean corpuscular volume; MPV, mean platelet volume; RBC, red blood cell; PLT, platelets; RDW, red cell distribution width; WBC, white blood cell. Most of the patients showed normocytic anaemia with mild anisopoikilocytosis. None of the reviewed cases showed morphological evidence of haemolysis, regardless of their clinical presentation. Seven patients had neutrophilia and two had neutropenia, while the neutrophil counts were normal in six patients. The lymphocyte count was at a lower normal range in eight patients (normal range 1·0–4·0 K/μl) and seven patients had lymphopenia. Besides these findings, the most common observation was the presence of atypical lymphocytes in most of the smears (14/15, 93·3%). These lymphocytes are medium to large in size with loosely condensed chromatin, and moderate to deep basophilic cytoplasm Fig 1A. Some of these cells demonstrate plasmacytoid morphology with eccentric nuclei and perinuclear hof Fig 1B. Some show visible nucleoli resembling immunoblasts Fig 1C. The atypical lymphocytes comprised 6·94 ± 4·30% of the total lymphocytes Fig 1D. It appears that the percentage of atypical lymphocytes in total lymphocytes does not correlate with the severity of the disease Table I. Additionally, two cases of bronchial alveolar lavage smears from two patients (no accompanying blood smear review) were reviewed due to the presence of numerous atypical lymphocytes with the same morphology as those found in the blood smear Fig 1E. Atypical lymphocytes in patients with COVID‐19. (A–C) Wright‐Giemsa stained peripheral blood smear showing representative forms of atypical lymphocytes observed in 15 cases of smear review (×100). (D) Percentages of indicated lymphocytes out of total lymphocytes in the patients with COVID‐19. Differential count of the indicated lymphocytes was performed; 200 lymphocytes were counted in each patient. (E) Wright‐Giemsa stained bronchial alveolar lavage smear from a patient with COVID‐19 (×60). (F) Wright‐Giemsa stain of the peripheral blood smear from a patient with infectious mononucleosis caused by Epstein–Barr virus infection (×100). These atypical lymphocytes are likely reactive to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Their morphology is different from Downey type II reactive lymphocytes Fig 1F that are commonly seen in other viral infections such as Epstein–Barr virus. In our reviewed 15 patients, Downey type II reactive lymphocytes were seen, but with a much lower frequency (0·50 ± 0·85% of the total lymphocytes). Additionally, lymphopenia is frequently seen in SARS and influenza and in both diseases has been recognised as a negative predictor of outcomes. , . However, presence of atypical lymphocytes is not a laboratory feature of influenza. The relative commonality of these cells compared to other viral infections, together with lymphopenia observed in many patients, may provide an important clue to further evaluate patients for COVID‐19. Future studies in the characterisation of these cells could be helpful in our understanding of the pathophysiology of the disease.
  3 in total

1.  Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality.

Authors:  Raúl Méndez; Rosario Menéndez; Isabel Amara-Elori; Laura Feced; Alba Piró; Paula Ramírez; Amparo Sempere; Alicia Ortega; Jesús F Bermejo-Martín; Antoni Torres
Journal:  J Infect       Date:  2019-04-06       Impact factor: 6.072

2.  Are atypical lymphocytes present with viral influenza-like illnesses (ILIs) in hospitalized adults?

Authors:  B A Cunha; J J Connolly; N Irshad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-01       Impact factor: 3.267

3.  Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets.

Authors:  Zhongping He; Chunhui Zhao; Qingming Dong; Hui Zhuang; Shujing Song; Guoai Peng; Dominic E Dwyer
Journal:  Int J Infect Dis       Date:  2005-08-10       Impact factor: 3.623

  3 in total
  12 in total

1.  Overview of the Haematological Effects of COVID-19 Infection.

Authors:  T M Wiggill; E S Mayne; J L Vaughan; S Louw
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  The Novel Coronavirus and Inflammation.

Authors:  J A George; E S Mayne
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes.

Authors:  Ian Gelarden; Jessica Nguyen; Juehua Gao; Qing Chen; Luisa Morales-Nebreda; Richard Wunderink; Lin Li; Joan S Chmiel; MaryAnn Hrisinko; Laura Marszalek; Sumaiya Momnani; Pinal Patel; Ricardo Sumugod; Qi Chao; Lawrence J Jennings; Teresa R Zembower; Peng Ji; Yi-Hua Chen
Journal:  Hum Pathol       Date:  2021-04-24       Impact factor: 3.526

Review 4.  Pleural effusion as a rare sign of anaplastic large-cell lymphoma in a COVID-19 patient: A case report and literature review.

Authors:  Omar Kamel; Laurence Rozen; Sophie Lecomte; Pierre Heimann; Anne Demulder
Journal:  Int J Lab Hematol       Date:  2021-03-24       Impact factor: 3.450

5.  Atypical lymphocyte morphology in SARS-CoV-2 infection.

Authors:  Siraj M El Jamal; Christian Salib; Aryeh Stock; Norlita I Uriarte-Haparnas; Benjamin S Glicksberg; Julie Teruya-Feldstein; Francine R Dembitzer; Girish N Nadkarni; Adolfo Firpo-Betancourt
Journal:  Pathol Res Pract       Date:  2020-06-10       Impact factor: 3.250

6.  Development of infectious mononucleosis as an unusual manifestation of COVID-19.

Authors:  Masatoshi Fukuda; Yuta Amano; Chisako Masumura; Makoto Ogawa; Hidenori Inohara
Journal:  Auris Nasus Larynx       Date:  2021-04-12       Impact factor: 2.119

7.  Cytopathology of bronchoalveolar lavages in COVID___19 pneumonia: A pilot study.

Authors:  Valentina Canini; Francesca Bono; Paolo Calzavacca; Giulia Capitoli; Giuseppe Foti; Filippo Fraggetta; Stefania Galimberti; Andrea Gianatti; Marco Giani; Ahmed Nasr; Giuseppe Paciocco; Fabio Pagni; Roberto Rona; Vincenzo L'Imperio
Journal:  Cancer Cytopathol       Date:  2021-03-10       Impact factor: 4.264

Review 8.  The clinical impact of COVID-19 epidemic in the hematologic setting.

Authors:  Carlo Finelli; Sarah Parisi
Journal:  Adv Biol Regul       Date:  2020-07-16

9.  Atypical lymphocytes in bronchoalveolar lavage fluid from patients with COVID-19 ARDS.

Authors:  Ronan M G Berg; Andreas Ronit; Sara B Rørvig; Ronni R Plovsing
Journal:  Pathol Res Pract       Date:  2020-10-08       Impact factor: 3.250

10.  SARS-CoV-2 pneumonia and atypical lymphocyte morphology in pleural fluid.

Authors:  Anna Merino; Javier Laguna; Angel Molina; Alexandru Vlagea; Oriol Sibila
Journal:  Int J Lab Hematol       Date:  2021-06-19       Impact factor: 3.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.